2025-12-19 - Analysis Report
Okay, here's a breakdown and analysis of RXRX (Recursion Pharmaceuticals Inc.) based on the provided data.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and high-throughput screening to discover and develop novel therapeutics.

**1) Return Comparison & Alpha/Beta Analysis**

*   **Return Rates:**
    *   RXRX Cumulative Return: -28.11%
    *   VOO Cumulative Return: 41.08%
    *   Divergence: -73.8 (Relative Divergence: 0.4)

*   **Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period captured by the cumulative return. The divergence of -73.8 indicates a substantial difference in performance.  The Relative Divergence of 0.4 suggests the current divergence is near the *lowest* end of its historical range relative to VOO, which may be interpreted as this is the *best* time to buy the stock. However, this should not be taken as financial advice.

*   **Alpha/Beta Analysis:**

    | Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
    |------------|--------|-------|---------|--------|--------|
    | 2021-2023  | 22.0%  | 81.0% | 26.0%   | -0.2   | 5.1    |
    | 2022-2024  | 11.0%  | 81.0% | -10.0%  | 0.1    | 3.5    |
    | 2023-2025  | 14.0%  | 80.0% | -49.0%  | 0.1    | 2.3    |

    *   **CAGR (Compound Annual Growth Rate):** The CAGR fluctuates, showing periods of growth but also decline, indicating volatility.
    *   **MDD (Maximum Drawdown):** A high MDD (around 80-81%) across all periods points to significant downside risk.
    *   **Alpha:** Alpha is generally poor. It was positive in 2021-2023, indicating outperformance compared to its benchmark, but turned negative for the subsequent periods, with a significant drop in 2023-2025 suggesting substantial underperformance.
    *   **Beta:** Beta consistently hovers around 0, indicating a very low systematic risk factor.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 4.44
*   **Last Market Close:** Price: 4.44, Previous Close: 4.68, Change: -5.13%
*   **5-day SMA:** 4.37
*   **20-day SMA:** 4.4773
*   **60-day SMA:** 5.0279

*   **Analysis:** The current price is below both the 20-day and 60-day SMAs, indicating a potential short-term downward trend. The recent 5.13% drop in the last market session reinforces this.

**3) Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommendation)
*   **RSI:** 45.41 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.3474 (Positive, but close to zero, suggesting weak bullish momentum.)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00)" -  This is a specific trading signal suggesting a strong buy recommendation with monthly investment.
*   **Recent (20 days) Relative Divergence Change:** -4.7 (Negative – short-term decline)
*   **Expected Return (%):** -540.8% (Extremely negative, projecting significant losses compared to the S&P 500 over a longer term). The reliability of this figure needs to be further scrutinized.

*   **Analysis:** The MRI suggests a medium investment risk profile. RSI is neutral. The PPO indicates slight positive momentum, which contrasts with the 20-day relative divergence change which indicates a short-term downward trend. The 'Hybrid Signal' is strongly bullish based on the MRI. The extremely negative expected return is very concerning, suggesting that, based on the algorithm, the stock is expected to severely underperform the market in the long run.

**4) Recent News & Significant Events**

*   The recent news headlines are generally *positive*, focusing on:
    *   **JPMorgan Upgrade:** Multiple sources report an upgrade by JPMorgan, which usually boosts investor confidence.
    *   **REC-4881 Trial Momentum:** Positive developments or anticipation regarding clinical trial data.
    *   **Analyst Perspectives:** Articles discussing the attractiveness of the stock and future potential.

*   **Analysis:**  The news sentiment, at least in the headlines, is positive, driven by analyst upgrades and positive trial outlook. This is a bullish signal, but needs to be viewed in light of the overall financial and technical picture.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.50 (~Hold)
*   **Number of Opinions:** 7
*   **Target Price:** Avg: 7.00, High: 11.00, Low: 3.00
*   **Recent Rating Changes:** Not available

*   **Analysis:** While the consensus is "Buy," the mean rating of 2.50 is closer to "Hold," which may indicate a lack of strong conviction among analysts. The average target price of $7.00 suggests a potential upside of ~57% from the current price.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|-------------|
| 2025-11-05 | -0.36 | 0.01 B$     |
| 2025-08-05 | -0.41 | 0.02 B$     |
| 2025-05-05 | -0.5  | 0.01 B$     |
| 2024-11-06 | -0.34 | 0.03 B$     |
| 2025-11-05 | -0.34 | 0.03 B$     |

*   **Analysis:** RXRX is consistently unprofitable. EPS is negative and revenue is very low and volatile, not showing a consistent upward trend. This indicates the company is currently burning cash.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%       |
| 2025-03-31 | $0.01B  | -47.31%      |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%      |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-09-30 | $1.05B  | -15.50% |
| 2025-06-30 | $0.92B  | -18.70% |
| 2025-03-31 | $0.93B  | -21.68% |
| 2024-12-31 | $1.03B  | -17.29% |
| 2024-09-30 | $0.52B  | -18.27% |

*   **Analysis:** Revenue is extremely low and inconsistent, indicating the company is heavily reliant on funding rather than product sales. The profit margin is consistently negative, often significantly so, indicating the company is not profitable at all. ROE (Return on Equity) is also consistently negative, reflecting its unprofitability. While equity is fluctuating, it's generally high, showing the company is well capitalized.

**7) Comprehensive Analysis**

RXRX presents a mixed and complex picture:

*   **Negatives:**
    *   **Significant Underperformance:**  RXRX has underperformed the S&P 500 substantially.
    *   **High Risk:** High MDD and negative Alpha indicate a volatile investment. The projected negative return is extremely concerning.
    *   **Unprofitability:** Consistent negative earnings, poor revenue, and negative profit margins highlight a fundamental weakness.
    *   **Technical Concerns:**  Price below key moving averages.
*   **Positives:**
    *   **Recent Positive News:** Analyst upgrades and trial optimism are positive catalysts.
    *   **Analyst Buy Consensus:** Analysts generally view the stock as a buy, with a significant upside potential implied by the average price target.
    *   **Strong Balance Sheet:** The company appears well-capitalized.
    *   **'Hybrid Signal' Suggests "Very Safe":** This bullish signal is a great indicator.

**Overall Conclusion:** RXRX appears to be a *high-risk, high-reward* investment. The company is fundamentally unprofitable but has the potential to significantly increase with trial outcomes and product commercialization. The recent news and analyst sentiment suggest potential upside, but the financial data and technical indicators warrant caution. Investors should carefully weigh the risks and potential rewards before investing in RXRX. The data is contradictory and additional analysis is likely needed.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.